middle east and africa cell therapy Market

The Middle East and Africa cell therapy market is expected to reach US$ 346.7 million by 2027 from US$ 234.4 million in 2019; it is anticipated to grow at a CAGR of 5.1% during 2019–2027.

The Middle East and Africa cell therapy market is growing primarily due to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and growing number of approvals for cell-based therapies. Factors such as high cost of cell therapy manufacturing restraining the growth of the market.     

Mainly stem cells are used for cell therapies because of their ability to differentiate specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy also has applications in the development of regenerative medicines.

The Middle East & Africa is hindered due to the burden of chronic diseases owing to the lack of proper healthcare system across the region and low awareness about the novel therapeutics available in the market. National Institute of Health of South Africa has reported that around 5.7 million people in the country were suffering from HIV, during 2016–2017. Network of Civil Society Organizations also reported that South Africa is experiencing the surge in the number of patients suffering from Noncommunicable Diseases (NCDs) such as heart diseases, stroke, cancer, diabetes, and chronic lung disease. According to the International Diabetes Federation (IDF) Diabetes Atlas 8th Edition, around 15.5 million adults of aged 20–79 years were having diabetes in Africa in 2017. According to Globocan 2018, prevalence for cervical cancer is around 11.3 %, i. e 119,284 cases have been registered in Africa in 2018. With such a huge patient pool and a huge scope of the market, many major players in the cell therapy market are investing in the region.

Similarly in the UAE, there is a high prevalence of diabetes. According to the International Diabetes Federation (IDF), 17.3% of the UAE population between the age of 20 and 79 years was suffering from type 2 diabetes in 2017. Over 1 million people are affected by diabetes in the UAE, placing the country at the 15th rank in the world for diabetic prevalence. According to the Department of Health Abu Dhabi, cancer is the third leading cause of death in Abu Dhabi and accounts for 16 % of total deaths.  

The COVID-19 pandemic has become the most significant challenge across the Middle East and Africa. Countries such as the UAE and Saudi Arabia have also registered a significant number of positive patients. In the initial phase of lockdown, various countries have witnessed disruptions in the supply of many instruments across the regions. Therefore, many organizations are collaborating with others to overcome this pandemic by using cell therapies in the treatment of COVID 19. For instance, UAE-based Abu Dhabi Stem Cells Center (ADSCC) has entered into collaboration agreement with Pluristem Therapeutics Inc. to develop cell therapies and regenerative medicines for the treatment of COVID-19.  

In 2019, the allogeneic segment accounted for a larger share of the Middle East and Africa cell therapy market. The growth of the market for this segment is attributed to the factors such as increasing number of product launch to accelerate the overall product availability for stem therapy using allogeneic stem cell therapeutics. However, the autologous segment is likely to register a higher CAGR in the market during the forecast period.  

A few of the significant secondary sources referred to while preparing the report on the Middle East and Africa cell therapy market are the World Health Organization (WHO), Centers of Disease Control and Prevention (CDC), National Institute of Health of South Africa, and Department of Health Abu Dhabi, Abu Dhabi Stem Cell Center (ADSCC).    

 .